Although a number of studies have focused on the linkage between IFN-induced transcripts or proteins and SLE disease activity, most of them suffer from sample-size limitations and essential clinical and therapeutic heterogeneity in SLE. This evidence concerns the gene IFNA1 and systemic lupus erythematosus.